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Background: Well-organised quality-controlled screening can substantially reduce the burden of cervical cancer
(CC). European guidelines (EuG) for quality assurance in CC screening provide guidance on all aspects of an organised
screening programme. Organised CC screening in Poland was introduced in 2007. The purpose of our study was to
analyse: (i) adherence of the programme to EuG; (ii) programme process and performance indicators; (iii) impact of the
programme on the incidence of and mortality from CC.
Methods: Available data on the policy, structure and functioning of the Polish programme were compared with
the major points of the EuG. Data on the process, and available performance indicators were drawn from the
screening database and other National Health Fund (NHF) systems. Joinpoint regression was used to assess changes in
CC incidence and mortality trends.
Results: The Polish programme adheres partially to EuG in terms of policy and organisation. Only a limited set of
performance indicators can be calculated due to screening database incompleteness or lack of linkage between
existing databases. The screening database does not include opportunistic smears collected within NHF-reimbursed or
private care. The organised programme coverage rate fluctuated from 21% to 27% between 2007-2013. In 2012 the
coverage reached 35% after combining both organised and opportunistic smears reimbursed by the NHF. In 2012
the number of smears reimbursed by NHF was 60% higher in opportunistic than in organised screening with
significant overlap. Data from the private sector are not recorded. Depending on years, 30-50% of women referred
for colposcopy/biopsy because of abnormal Pap smears were managed within the programme. The age-standardised
CC incidence and mortality dropped linearly between 1999 and 2011 without evidence of a period effect.
Conclusions: The Polish organised cervical screening programme is only partially adherent to evidence-based EuG.
Its implementation has not influenced the burden of CC in the country so far. Changes with special focus on increasing
coverage, development of information systems and assessment of quality are required to increase programme adherence
to EuG and to measure its effectiveness. Our findings may be useful to improve the Polish programme and those
implemented or planned in other countries.
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There is a widely accepted consensus based on data
from cohort [1], case-control [1,2] and modelling [3]
studies that cytological screening followed by treatment
of preinvasive cervical neoplasia results in a substantial
reduction of the incidence of and mortality from cervical
cancer (CC). The burden of CC is geographically hetero-
geneous throughout the world with highest incidence in
low income countries lacking effective screening pro-
grammes [4]. Poland has a medium incidence of and
mortality from CC among European countries with
world-age standardised rates of 9.8/100 000 and 4.8/100
000 respectively in 2011 [5].
Well-organised high-quality cytological screening may
reduce CC incidence substantially. The successive steps
of successful screening include information and invita-
tion of the eligible target population, performance of the
screening test, follow-up and treatment of the screen-
detected neoplasia [6-8].
CC prevention in Poland has been present for over
50 years now with opportunistic screening run since the
1950ties and the first active programme (for personal in-
vitation) implemented locally in one district of Warsaw
in 1976 [9]. However, active country-wide population-
based screening was absent. In 2007, such a programme
was set up with full registration of invitations, responses
to invitations, results of Pap smears and other proce-
dures in an internet-based electronic registry.
The purpose of this study was to analyse the adherence
of the Polish programme to the European Guidelines
(EuG) for Quality Assurance in Cervical Cancer Screening
[7,8]. We also summarised the course and effects of the
first seven years (over two screening rounds) of the
programme in Poland.
Methods
The use of data for this publication was approved by
National Health Fund (NHF) authorities. The data for
this study was drawn collectively from NHF databases
and other available sources. All records were coded in such
a way that identification of individuals was impossible.
Policy, structure, parameters and performance indicators
of the programme
Data on the policy, structure and functioning of the
organised cervical screening programme were drawn
from published documents of the Director of the NHF
in Poland [10], previously published reports [11-17], as
well as analysis of the internet-based electronic data base
SIMP (abbreviated from Polish: System Informatyczny
Monitorowania Profilaktyki; English: Informatic System
for Monitoring of Prevention) [18].
Organised CC screening programme in Poland is a
public healthcare intervention organised by the Ministryof Health and the NHF. In its current version it was
started in 2006/2007. Every three years, all women aged
25-59 identified from the lists of General Practitioners’
(GP) practices (which cover ~95% of population of
women) are sent a written invitation via ordinary mail to
have a Pap smear taken. The invitations without a set
time and date of appointment are sent after a 36-month
interval from a previous normal smear performed in the
programme. HPV- and HIV-infected women and those
taking immunosuppressants are eligible to perform
smears every year. No reminder letters are sent to non-
responders. A gynaecological clinic in the neighbourhood
of woman’s GP practice is suggested on the invitation, but
a Pap smear may be taken by a gynaecologist or a certified
midwife in any of the ambulatory clinics in the country
which provide gynaecological and obstetrical care reim-
bursed by the NHF. Since 2014, certified family mid-
wives are also eligible to collect smears at GPs’
practices. The smears are processed by cytotechnicians
and pathologists in selected cytological laboratories. The
laboratories evaluating smears within the programme
must fulfill explicit criteria and are expected to perform
internal quality control. This includes full reviewing of
10% of negative slides or rapid reviewing of all negative
slides and control of all positive slides by a specialist
pathologist. All labs undergo quality audits annually by
external pathologists according to a protocol elaborated
by the Central Coordinating Office. Underperforming
labs are excluded from the programme. The smears are
interpreted according to a modification of the Bethesda
system [19] (See Additional file 1). Women with abnor-
mal Pap smear results are supposed to undergo triage
within the programme via: 1) repeated Pap smear (ASC-
US - Atypical Squamous Cells of Undetermined Signi-
ficance, LSIL – Low Grade Squamous Intraepithelial
Lesion), or 2) colposcopy/colposcopically directed bi-
opsy (ASC-US, LSIL, ASC-H - Atypical Squamous Cells -
Cannot Exclude High Grade Squamous Intraepithelial
Lesion, HSIL – High Grade Squamous Intraepithelial
Lesion, AGC – Atypical Glandular Cells, SCC - Squamous
Cell Carcinoma). If triage procedures are performed
within the programme, the results are recorded in the
SIMP. Human Papillomavirus (HPV) testing recom-
mended for triage of ASC-US and LSIL [20] is not
available in the programme but can be performed
within NHF-reimbursed gynaecological services. Med-
ical procedures in opportunistic screening and manage-
ment of screen-positive women are reimbursed by the
NHF within ambulatory and hospital gynaecological
care outside the screening programme but results are
not recorded in SIMP. Despite recommendations [21],
there are no obligatory certification or quality require-
ments for cytological laboratories operating outside the
screening programme.
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poscopy and biopsies performed within the programme
are fully covered by the NHF. Costs of administration,
coordination of the programme as well as mailing of
invitations are covered by the Polish Ministry of Health
from the funds of the National Programme for Fight
Against Cancer Act [22]. The screening programme is
coordinated by the Ministry of Health, a Central and 16
Regional Coordinating Offices (RCO). The RCOs send
invitations to women and are supposed to monitor,
evaluate and perform quality control of the programme.
They are also responsible for training of personnel in-
volved in the program and for setting up interventions to
increase the programme coverage. These interventions in-
clude, but are not limited to: local and countrywide media
campaigns, cooperation with local authorities, governmen-
tal and non-governmental organisations, direct meetings
with programme participants and healthcare providers,
promotion of the programme via countrywide and local
cultural and social events.
Cancer registration
The National Cancer Registry (NCR) collects data via its
16 regional offices on cancer incidence, mortality, mor-
bidity and survival in Poland [5]. Data on incidence
come from electronic or traditional paper reports [5,23].
87% of diagnoses were confirmed by pathology codes in
2011 [24]. Data on cancer mortality come from Central
Statistical Office and are based on death certificates.
Since adherence of the programme to some points of
the EuG [7,8] cannot be measured in a quantitative
manner, a descriptive comparison of the valid recom-
mendations, legislative acts and real-life clinical practice
to the major points of the EuG is given. The adherence
of the programme was qualified as full, partial or absent
according to the level of agreement between the EuG
and the Polish programme. Data on the available param-
eters and outcome measures of the CC screening
programme in Poland were drawn from SIMP and other
NHF electronic databases. We analysed which of the
performance parameters in CC screening recommended
by the EuG [7] can be calculated for Poland.
Burden of invasive cervical cancer
World age-standardised incidence and mortality rates of
CC in Poland were extracted from the NCR database in
Poland [5]. Rates were aggregated by calendar year and
10-year age groups (except for the oldest women cate-
gorised as ≥ 80 years). Joinpoint regression was used to
analyse time trends (Joinpoint Regression Software) [25].
Joinpoint regression identifies periods with distinct lin-
ear slopes that can be separated by joinpoints, where the
slope of the trends changes significantly [26]. For eachlinear segment, the annual percent change (APC) and
corresponding 95% confidence intervals (95% CI) were
calculated. Analysis was performed for a 13-year period
from 1999 to 2011 which encompassed years of imple-
mentation of the screening programme (2006/2007).
Results
Policy and structure of the programme
The adherence of the most important constituents of
the Polish programme to EuG is summarised in Table 1.
The Polish programme is fully adherent to the EuG in
terms of: type of screening test; interval between tests
with normal results; and the age to start testing (Table 1).
Partial adherence is noted for: the type of screening and
screening policy; the age to stop testing; the issue of
older women who have never attended screening; dis-
couragement for opportunistic screening; information
system; publication of programme indicators and new
screening technologies (Table 1).
The adherence of organised screening in Poland to
EuG for cytology laboratories, histopathology, manage-
ment of screen-positive women is presented in Table 2.
The Polish programme is fully adherent to EuG in the
aspect of: collection, preparation, handling, staining,
screening of samples and reporting of the results; and
partially adherent regarding: grading of cytological
abnormalities; histopathology as the gold standard and
its terminology; availability of cytological results for
pathologists, accuracy of histological diagnosis, correl-
ation with cytological results; and management of
screen-positive women (Table 2) [27-32]. No major
points in the Polish screening programme have been
identified to be completely non-adherent to EuG.
Parameters and performance indicators of the programme
Selected available parameters of the organised and reim-
bursed opportunistic screening are presented in Table 3.
The data collected in SIMP and other systems enable
calculation of the following performance indicators [7]:
programme extension; coverage of the target population
by invitation; coverage of the target population by smear
tests; compliance to invitation; distribution of screened
women by the results of cytology; referral rate for repeat
cytology; compliance to referral for repeat cytology;
referral rate to colposcopy; positive predictive value of re-
ferral to colposcopy; compliance to referral to colposcopy.
The following indicators cannot be automatically
calculated based on the available systems: smear con-
sumption; incidence of invasive cancer in unscreened or
underscreened women in a given interval; test specifi-
city; detection rate by histological diagnosis; treatment of
high-grade intraepithelial lesions; proportion of women
hysterectomised on screen-detected intraepithelial lesions;
proportion of women treated for Cervical Intraepithelial
Table 1 Adherence of the organised cervical screening programme in Poland to European Guidelines for Quality Assurance in Cervical Cancer Screening
[7,8] – screening policy, organisation, monitoring, evaluation and new screening technologies
Point of the guideline Recommendation of the guidelines Adherence of the Polish programme to the guideline
Legal regulations, guidelines and protocols Implementation and clinical practice
Screening type Population-based public healthcare programme,
with identification and personal invitation of each
woman in the eligible target population
Partial adherence
Full adherence. Postage of invitations is not regulara.
Screening policy Selection of screening test systems, determining
target age group and interval between normal
test results, establishing follow-up and treatment
strategies for screen positive women
Partial adherence
Treatment strategies are not included in
organised screening policy.
Large part of triage of abnormal Pap smears is
performed outside the programmeb.
Screening test Cytology Full adherence
Interval between tests with normal results 3-5 years Full adherence
Age to start testing 20-30 years of age Full adherence
Age to stop testing 60-65 years of age. Stopping screening in older
women who have had three or more consecutive
recent normal cytology results.
Partial adherence
No system of stopping organised screening in
older women with previous normal smears has
been elaborated.
Opportunistic screening in older women is
reimbursed and performed regardless of
screening history.
Issue of older women who have never
attended screening
Special attention should be paid to older women
who have never attended screening as they are
at increased risk for CC
Partial adherence
No systemic solutions have been undertaken to
reach women older than 59 who have never
attended screening despite unfavourable
epidemiological datac. Women older than 59 are
not allowed to undergo organised testing
regardless of screening history.
Coordinating Offices and the Ministry of Health
undertake multiple actions to increase coverage
of the programme and to reach non-attenders
among women at the screening age 25-59.
Opportunistic screening Opportunistic screening should be discouraged.
It leads to “overscreening” of selected populations
and “underscreening” of groups with less
socioeconomic status.
Partial adherence
Educational campaigns led by Coordinating Offices
have been introduced to discourage opportunistic
screening but it is reimbursed and recommended
in pregnancy [43].
Private-based opportunistic screening is popular
but its extend and outcomes has never been
precisely assessed. There are non-governmental
initiatives encouraging opportunistic screening
at one year intervals in young age groups [44].
Information system Implementation of the information system for
managing the screening programme; computing
the indicators of attendance, compliance, quality
and impact and providing feedback.
Partial adherence
The implemented system (SIMP) enables
computation of selected indicators from organised
screening only.
Only partial data on screening outcomes have
been computed and analysed [11-17].
Linkage between information systems and
databases
An appropriate legal framework is required for
registration of individual data and linkage between
population databases, screening files, cancer and
mortality registers.
Partial adherence
A screening registry (SIMP) is implemented but
not fully integrated with other existing systems
and some registries are lackingd.
There is routine input of data into several
systems, but they are not integrated.
Publication of programme indicators Indicators of screening programme extension and
quality need to be published regularly.
Partial adherence
Data available in SIMP are insufficient to generate
some of the crucial indicators for publication.
Only selected indicators of the programme were














Table 1 Adherence of the organised cervical screening programme in Poland to European Guidelines for Quality Assurance in Cervical Cancer Screening
[7,8] – screening policy, organisation, monitoring, evaluation and new screening technologies (Continued)
New screening technologies Before routine implementation of new screening
technologies phased piloting or even controlled
randomised implementation should be executed
for its evaluation under real-life conditions.
Partial adherence
Randomisation of screening policies is technically
feasible. Pilot programme of primary HPV testing
is on the way in two regions.
Comprehensive evaluation of pilot HPV testing
will be hampered by partial availability of data
on the outcomes in SIMP.
Footnotes: aThe postage is infrequent during the first 3-6 months of each year because of the late signature of contracts between the Ministry of Health and the Regional Coordinating Offices. bPricing of the triage
(colposcopy/biopsy) is lower in the programme than outside within NHF-reimbursed procedures. cCrude incidence rates of CC in Poland still remain high to the age of 84 [5].dData from SIMP are partially linked with
treatment databases of the National Health Fund but not with National Cancer Registry. SIMP enables reporting of data to the NCR but not obtaining data from the NCR e.g. to identify false negative Pap smear or
colposcopy/histology results and interval cancers. Histology results of false negative cytology cases are not available in the SIMP; only partial data on type of treatment is available. The SIMP is linked to mortality













Table 2 Adherence of the organised cervical screening programme in Poland to European Guidelines for Quality Assurance in Cervical Cancer Screening
[7,8,27-32] – guidelines for cytology laboratories, histopathology, management of screen-positive women
Point of the guideline Recommendation of the guidelines Adherence of the polish programme to the guideline
Legal regulations, guidelines and protocols Implementation and clinical practice
Collection, preparation, handling, staining,
screening of samples and reporting of
the results
Guidelines must be followed to assure adequate
collection and preparation of the samples. The
quality of the cytology laboratory depends on
adequate handling, staining, screening of slides
and reporting of results.
Full adherence
Grading of cytological abnormalities Uniform grading of cellular abnormalities is an
essential condition for registration and comparisons.
Laboratories should apply only a nationally agreed
terminology for cytology which is translatable into
the Bethesda Reporting System
Partial adherence
The grading system is not fully compatible
with the Bethesda 2001 terminology and
requires modification (see Additional file 1)
Full adherence to established grading
system
Histopathology as the gold standard and
its terminology
Histopathology provides the final diagnosis for
treatment, is the gold standard for quality control
of cytology and colposcopy and is the source of
data for cancer registry. Histopathology standards
should be monitored and are on the basis of CIN
or other internationally agreed-upon terminology.
Partial adherence
There is no electronic database of cervical
histology results obtained outside the
programme. No systematic quality control
for histopathology is implemented into the
screening programme. There is no automatic
or obligatory reporting of histology from the
labs to cancer registry.
Only partial data on histopathology of
invasive cancers are collected in NCR.
Availability of cytological results for
pathologists, accuracy of histological
diagnosis, correlation with cytological results.
Histopathologists should be aware and familiar
with, the nature of cytological changes that may
be relevant to their reports. The accuracy of
histopathological diagnosis depends on adequate
samples, obtained by colposcopically directed
biopsies (with endocervical curettage when necessary)
or excision of the transformation zone or conisation,
macroscopic description, processing, microscopic
interpretation and quality management correlating
cytological and histological diagnosis.
Partial adherence
There is no central histopathology database
and therefore cervical histology results
obtained outside the programme are not
readily available for analyses and cyto-histological
correlations.
Tissue material from biopsies is often
assessed at different laboratories than
the ones assessing the cytological slides.
The availability of data on cytological
abnormalities to the pathologists is partiala.
Only single local reports exist [51] on local
correlations between cytology and
histopathology.
Management of screen-positive women A women with a high-grade cytological lesion, a
repeated low-grade lesion or an equivocal cytology
results and a positive HPV test should be referred
for colposcopy. Guidelines are provided for the
management of ASC-US and HSIL. For LSIL repeat
cytology or colposcopy are acceptable options and
HPV testing in older women can be considered.
Quality assurance and collection of data on patient
management and follow-up are important in women
with abnormal cytology.
Partial adherence
HPV testing is not reimbursed within the
programme for triage of abnormal Pap results.
Only partial data on management of women
with abnormal smears are available in SIMP.
Repeat cytology and other triage
procedures are commonly performed
outside the programme and their results
are not registered. Data on triage,
management and follow-up are not
evaluated and not analysed on regular
bases.













Table 3 Selected available parameters on cervical cancer screening in Poland after implementation of organised
screening programme (2007-2013)
Parameter/year 2007 2008 2009 2010 2011 2012 2013
Population eligible for screening – 1/3 of the population of
women aged 25-59 years
3 227 918 3 252 888 3 274 036 3 289 805 3 293 187 3 293 976 3 290 725
Number of invitations sent 6 027 714 2 682 051 1 595 319 3 202 927 3 357 114 3 413 678 3 220 582
Coverage of population by invitations 186.7% 82.5% 48.7% 97.4% 101.9% 103.6% 97.9%
Compliance to invitations* 11.2% 12.8% 13.1% 11.5% 11.2% 10.7% 9.9%
Number of women screened within the programme 686 380 794 486 876 646 797 442 804 847 765 301 696 894
Coverage rate of organised screening 21.3% 24.4% 26.8% 24.2% 24.4% 23.2% 21.2%
Total number of Pap smears collected within NHF outside
the screening programme
NA NA NA NA NA 1 288 358 NA
Total number of Pap smears collected in women aged
25-59 years within NHF outside the screening programme
NA NA NA NA NA 807 129 NA
Number of women screened outside the programme within
NHF opportunistic screening and not screened within the
programme within the current 3-year interval
NA NA NA NA NA 411 216 NA
Combined coverage of organised and opportunistic
screening within NHF
NA NA NA NA NA 35.7% NA
Number of women referred for colposcopy/biopsy within
the programme
4 917 6 149 9 158 9 216 9 850 9 879 10 496
% of women referred for colposcopy/biopsy who underwent
colposcopy/biopsy within the programme
41.1% 50.5% 46.8% 34.2% 31.7% 31.2% 29.7%
Legend: *Data with a 6-month cut-off date generated on 30th of June of each following year. Data on women screened within opportunistic screening provided
within private gynaecological care and private insurance plans are unknown since there is no central registry of opportunistic smears. NA - data not available.
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after normal and after abnormal cytology; proportion of
women with cytology negative for squamous intraepithe-
lial lesions, 6 months after treatment.
At this stage, smear consumption can be calculated by
merging data from SIMP with data on opportunistic NHF-
reimbursed Pap smears but not automatically on regular
basis. Pap smear consumption in private care and private
insurance plans is not recorded. Indicators such as inci-
dence of cervical cancer in unscreened or underscreened
women in a given interval, cancer incidence after normal or
after abnormal cytology, treatment of high-grade intrae-
pithelial lesions, proportion of women hysterectomised on
screen-detected lesions theoretically can be calculated
based on data from NHF treatment databases containing
International Classification of Diseases version 10 (ICD10)
codes and types of procedures with International Classifica-
tion System for Surgical, Diagnostic and Therapeutic Proce-
dures (ICD-9-CM) codes. However at present it would
require special searches in the electronic systems and the
quality of these data is undetermined since they contain no
histological reports. NCR database and SIMP have not been
connected electronically so far and computation of certain
indicators is therefore still impossible at present.
Burden of invasive cervical cancer
Both age-standardised CC incidence and mortality rates
have been decreasing steadily for the last decade inPoland (Figure 1). Figure 2 shows the age-standardised
incidence rates (ASIR), and mortality rates (ASMR), as
well as the annual percentage change (APC) with 95% CIs
for CC in Poland (1999-2011). The declines in both
standardised rates decreased significantly in the period
1999-2011 with the APC for incidence: -2.6, 95% CI: -3.1
to - 2.1 and the APC for mortality: -2.2, 95% CIN: -2.8
to -1.7 (Figure 2). The decreases in incidence were
significant in all 10-year age groups apart from women
aged 60-69 years (Figure 2). The age-specific mortality
rates dropped significantly in all age groups apart from
women aged 50-59 and 60-69 years (Figure 2). The
linear slopes were constant in all age groups and no
significant trend changes were identified over the ana-
lysed period (1999-2011) encompassing implementation
of the programme (2006/2007) (Figure 2).
Discussion
The implementation of organised cervical screening pro-
grammes in the member states of the European Union
was recommended by the European Council in 2003, in
agreement with EuG [7]. After an initial phase between
2004-2006, an organised programme was rolled out in
its current state in 2007 in Poland. The trend of the
burden of CC may be indicative of the impact of the
enrolment of preventive programmes. Our initial ana-
lysis of the age-specific trends in CC incidence and mor-
tality indicates no evidence of a significant period effect
Figure 1 Cervical cancer burden in Poland between 1999 and 2011.
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(Figure 2). We consider these results with caution being
aware that data from a simple age-period trend analysis
might not be a sufficient proof of programme ineffective-
ness. Additional more complex analyses utilising linkage
between screening and cancer registries and incorporating
data on changes in exposure to risk factors, changes in
coverage and quality of non-monitored screening will be re-
quired to assess the impact of the implemented screening
on the CC burden in Poland over a longer time perspective.
Our analysis reveals that organised CC screening in
Poland is only partially adherent to EuG and there are a
number of issues which require further insight and ac-
tions. The coverage and quality of screening seem to be
most important. No registration of Pap smears collected
outside the organised screening hampers comprehensive
assessment of the coverage. In 2012 the coverage rate
of the NHF-reimbursed (organised and opportunistic)
screening reached 36% (Table 3). However according to
survey-based data from Central Statistical Office in
Poland, 86% of women aged 20-69 at least once in their
lifetime have undergone pap testing and 73% of women
at this age underwent a pap test within the preceding
three-year interval [33]. Although, these questionnaire-
based results probably overestimate the real coverage
[34], they indicate that many women participate in the
private-based opportunistic screening.
Organized screening is more effective and more cost-
effective [7], however in many countries opportunistic
screening is the only or dominating way of secondary
prevention [35,36]. In Poland a direct shift fromopportunistic to organised screening may be difficult to
achieve in a short time due to habits of women and
healthcare providers. Therefore integration of both screen-
ing modalities should be considered, as in other coun-
tries [35]. Analysis of systems integrating both types of
screening in countries with longer experience such as
Finland [37], the Netherlands [38], Denmark [39] and
France [40] should be performed to select a model which
fits best into Polish conditions. Nevertheless, more re-
search on the reasons for non-attendance to the organised
programme is required in order to find targeted solutions.
Very recent findings from Finland indicate that carefully
managed invitation/reminder letters with scheduled ap-
pointments and self-sampling options offered to non-
attending women can increase organised programme ef-
fectiveness [41]. On the other hand, Belgian experience
shows that sending invitations hardly influences screening
coverage in a country with a long tradition of opportunis-
tic screening [42]. Appropriate trials run in the real-life
conditions are required to demonstrate the effectiveness
of actions planned in Poland to increase organised screen-
ing coverage before costly implementation.
EuG propose discouragement of yearly opportunistic
screening but opportunistic smears are still reimbursed
by NHF and are recommended in pregnancy by the
Ministry of Health [43] and by other actively operating
non-governmental organisations in Poland [44]. No re-
imbursement for opportunistic smears could reduce
overscreening in some cohorts, promote screening at
recommended intervals and drive shifts towards orga-
nised screening [42]. However, stopping reimbursement
Figure 2 World age-standardised rates of incidence of and mortality
from cervical cancer in Poland (1999-2011). Figure legend: ASIR -
Age-Standardised Incidence Rate; ASMR - Age-Standardised Mortality
Rate; ^ - The Annual Percent Change (APC) is significantly different
from zero; 95% CI - 95% confidence interval.
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for women and most of gynaecologists in Poland in the
initial years. Nonetheless, it may induce better adherence
of the real-life practice to the EuG and finally result in
increased programme effectiveness. In Poland smears
outside the screening programme are used and reim-
bursed for many clinical indications such as: triage of
previously abnormal cytology, follow-up after treatment
of CIN and cancer. A reimbursement protocol would
have to be developed to reimburse smears for the above
mentioned indications but not for screening beyond the
recommended target age group and screening interval.
As explained in results, assessment of screening per-
formance as recommended in EuG is currently impos-
sible in Poland since several activities take place outside
the organised programme, are not recorded and/or are
inaccessible by lack of effective data linkage. Participa-
tion in the screening programme requires signing a con-
sent for collection, storage and processing of womens’
personal data. However an additional legal framework is
needed for data collection, storage, processing, including
linkage of screening, follow-up and cancer register
allowing to run and to evaluate the programme [7].
Although cytological labs in the programme undergo
external quality audits every year, their results have not
been published and assessed to reach conclusive points
for programme improvements. Some of the cytological
labs working outside the programme in the opportunistic
screening are not monitored and their quality is unknown.
Data on mortality audits and interval cancers have been
published for some countries [45], but no such attempts
have been made for Poland yet. Quality of colposcopy, and
histopathology should be assured as well [46].
Consideration of new evidence regarding better per-
formance of primary HPV-based compared to cytology-
based screening is important for the country [47]. A
pilot study on the use of HPV testing as a primary
screening co-test has started in two regions. However re-
sults of HPV testing are not registered in SIMP which
will hamper performance evaluation.
Implementation of a cancer screening programme can
be divided into seven phases: (1) pre- planning, (2) plan-
ning, (3) feasibility testing, (4) piloting or trial imple-
mentation, (5) scaling up from pilot to service, (6)
running, and (7) sustaining the full-scale programme
[48]. For each phase, a substantial number of specified
conditions have to be met. The Polish experience shows
that some of the major points such as feasibility testing
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detailed conditions such as the incorporation of an IT-
system linking registries and a comprehensive system
covering all steps in the screening process, development
of a quality assurance plan and publication of its results
have not been fully implemented thus far.
There may be other factors than the performance of
organised screening, which may explain the higher rates
of mortality from CC in Poland than in most of Western
European countries [49]. The exposure to risk factors as-
sociated with cervical cancer as well as the effectiveness
of diagnosis and treatment of women with invasive or
preinvasive disease are among them and require further
insight [50].
Conclusions
Polish organised cervical screening programme is only par-
tially adherent to evidence based EuG. Its implementation
has had no impact on the burden of CC in the country so
far. Comprehensive research of non-attendance to organised
screening and targeted actions are required to increase its
coverage. Development of information systems to obtain
data on opportunistic smears and histology reports, and
linkage with cancer registry data is required to increase
programme adherence to EuG and to measure its effective-
ness. Our findings may be useful to improve the Polish
programme and those implemented or planned in other
countries.
Additional file
Additional file 1: The system used for classification of Pap smear
results in organised cervical cancer screening programme in Poland
– current version in use from 1st April 2014.
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